Table 2.
Studies on prevalence of latent tuberculosis infection included in the systematic review and their main findings (n = 52)
First Author | Year of publication | Country of study | Population | Country / Region of origin | Period of data collection | Setting | Sample size (n) |
Women (%) |
Study design | Diagnostic test | TST cutoff point (mm) | Prevalence of LTBI (%) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Men | Women | Overall | |||||||||||||
Start | End | ||||||||||||||
Choi [6] | 2007 | Republic of Korea | Refugee | North Korea | 1999 | 2006 | Routine screening | 1112 c | 63.4 | Cross sectional | TST | 10 | NI | NI | 81.47 |
Chaves [43] | 2009 | Australia | Refugee | Myanmar; Thailand | 2004 | 2008 | Symptomatic | 149a,c | 48.7 | Cohort | TST / IGRA | 10 | NI | NI | 70.47 |
Diel [52] | 2004 | Germany | Asylum Seeker | Afghanistan; Turkey; Iran; Burkina Faso; Socialist Federal Republic of Yugoslavia; Sierra Leone; Russia; Guinea; Togo | 1997 | 2002 | Both | 12,176b | NI | Cohort | TST | NI | NI | NI | 62.00 |
Tafuri [10] | 2011 | Italy | Asylum Seeker | Asia; Eritrea; Gambia; Ghana; Nigeria; North Africa; Somalia; Tunisia | 2009 | 2009 | Routine screening | 982c | 14.4 | Cross sectional | TST | 10 | 63.1 | 46.2 | 60.69 |
Lowther [45] | 2012 | USA | Refugee | Sub-Saharan Africa; South and Southeast | 2000 | 2007 | Routine screening | 11,615c | 44.8 | Cohort | TST | NI | NI | NI | 60.55 |
Baker [75] | 2009 | USA | Refugee | Somalia; Ethiopia; Liberia; Eritrea; Ghana; Zimbabwe; Ukraine; Russia Federation; China | 2006 | 2007 | Routine screening | 195c | 65.6 | Cohort | TST / IGRA | 10 | 65.7 | 32.0 | 55.38 |
Winje [60] | 2008 | Norway | Asylum Seeker | Asia. Europe; Africa | 2005 | 2006 | Routine screening | 912c | 24.9 | Cross sectional | TST / IGRA | 6 | NI | NI | 53.95 |
Lim [57] | 2016 | Canada | Refugee | Tibet | 2014 | 2016 | Routine screening | 163c | 51.11 | Cohort | TST / IGRA | NI | 54.2 | 43.8 | 51.53 |
Kowatsch-Beyer [76] | 2013 | USA | Refugee | Africa; East Asia; Eastern Europe; South Asia; Latin America | 2008 | 2008 | Routine screening | 224b | 47.8 | Cohort | TST | 5 | NI | NI | 51.34 |
Varkey [49] | 2007 | USA | Refugee | Africa; Europe; Asia; Central and South America | 1997 | 2001 | Routine screening | 9842c | 47.7 | Cohort | TST | 10 | 57.2 | 45.2 | 50.70 |
Watts [77] | 2017 | USA | Mixed | Africa; America; Europe; Eastern Mediterranean; Southeast Asia; West Pacific | 1995 | 2012 | Symptomatic | 6669b | 47 | Cross sectional | TST | 10 | 54.2 | 45.7 | 50.21 |
Padovese [78] | 2013 | Malta | Asylum Seeker | Somalia; Eritrea; Ethiopia; Western Africa | 2010 | 2011 | Routine screening | 500b | 18.8 | Cross sectional | TST / IGRA | 10 | NI | NI | 49.60 |
Liu [79] | 2009 | USA | Refugee | Ukraine; Vietnam; Somalia; Bosnia; Sudan | 1999 | 2005 | Routine screening | 9132c | 40.2 | Cohort | NI | NI | NI | NI | 49.17 |
Harstad [80] | 2009 | Norway | Asylum Seeker | Iraq; Somalia; Russia; Afghanistan; Serbia and Montenegro | 2005 | 2006 | Routine screening | 4526 b | 30.6 | Cohort | TST / IGRA | 6 | NI | NI | 47.61 |
Ouimet [31] | 2008 | Canada | Asylum Seeker | India; Pakistan; Guinea; Congo; Nigeria; Ivory Coast; Cameroon; Siri Lanka; Mexico; Zimbabwe | 2000 | 2004 | Symptomatic | 231 c | 43.2 | Cross sectional | TST | NI | NI | NI | 45.89 |
Weinfurter [81] | 2011 | USA | Refugee | NI | 2004 | 2006 | Routine screening | 594c | 47.8 | Cross sectional | TST / IGRA | 5 | NI | NI | 45.62 |
Pottie [82] | 2007 | Canada | Refugee | Sub-Saharan Africa; North Africa; Middle East; Eastern Europe | 2004 | 2005 | Routine screening | 112 b | 59.8 | Cohort | TST | 10 | 55.6 | 34.3 | 42.86 |
Moreno [83] | 2006 | USA | Mixed | Africa; Latin America; Asia; Europe | 1998 | 2001 | Routine screening | 101 c | 43.2 | Cohort | TST | NI | NI | NI | 41.58 |
Bertelsen [84] | 2016 | USA | Asylum Seeker | Sub-Saharan Africa; Asia; Eastern Europe; Middle East; Latin America and Caribbean; Western Europe | 2012 | 2014 | Routine screening | 160 c | 33.8 | Cohort | TST / IGRA | NI | NI | NI | 40.62 |
Chai [64] | 2013 | USA | Mixed | Ethiopia; Cameroon; Eritrea; Sierra Leone; Togo; Vietnam; Sudan; Democratic Republic of Congo; Columbia | 2003 | 2007 | Routine screening | 611 c | 43.0 | Cohort | TST | 10 | NI | NI | 39.12 |
Bua [51] | 2016 | Italy | Mixed | Nigeria; Mali; Senegal; Bangladesh; Gambia; Guinea; Nigeria; Ghana; Togo | NI | NI | Routine screening | 109 b | NI | Cross sectional | TST / IGRA | 5 | NI | NI | 38.53 |
Lobato [59] | 2008 | USA | Refugee | Bosnia; Vietnam; Somalia; Congo; Eritrea; Haiti; Cambodia | 1996 | 2005 | Routine screening | 4904 c | NI | Cohort | NI | NI | NI | NI | 38.38 |
Subedi [73] | 2015 | USA | Refugee | Bhutan; Burma | 2010 | 2012 | Routine screening | 149 b | 46.3 | Cohort | TST / IGRA | 10 | NI | NI | 38.26 |
Goldberg [85] | 2004 | USA | Refugee | Soviet Union; Yugoslavia; Somalia | 1999 | 2000 | Routine screening | 2194 c | NI | Cohort | TST | 10 | NI | NI | 37.06 |
Hobbs [58] | 2002 | New Zealand | Asylum Seeker | Iran; Afghanistan; Siri Lanka; Czech Republic; Kuwait; Somalia; Iraq | 1999 | 2000 | Routine screening | 869 c | 31.9 | Cross sectional | TST | 10 | NI | NI | 36.36 |
Rennert-May [62] | 2016 | Canada | Refugee | Sub-Saharan Africa; Middle East; South Asia; East and Southeast Asia | 2009 | 2011 | Routine screening | 746 c | 50.1 | Cohort | TST / IGRA | NI | NI | NI | 35.52 |
Board [86] | 2016 | USA | Refugee | Southeast Asia; South Asia; Middle East; Sub-Saharan Africa | 2010 | 2013 | Routine screening | 9860b | 45.8 | Cross sectional | TST / IGRA | 10 | 36.2 | 29.2 | 32.95 |
Nisbet [4] | 2007 | New Zealand | Refugee | Ethiopia; Somalia; Vietnam | 1993 | 2004 | Routine screening | 100b | 44.0 | Cohort | TST | 5 | NI | NI | 32.00 |
Trauer [65] | 2011 | Australia | Refugee | Africa; Eastern Mediterranean; Southeast Asia | 2006 | 2009 | Routine screening | 458 † | 56.1 | Cohort | TST | 10 | 36.0 | 28.6 | 31.88 |
Hensel [87] | 2016 | USA | Refugee | Burma; Bhutan; Iraq; Somalia | 2013 | 2014 | Routine screening | 694 c | 45.0 | Cross sectional | IGRA | NA | 33.6 | 29.1 | 31.84 |
Walters [88] | 2016 | USA | Mixed | Sub-Saharan Africa; Eastern Asia and Pacific; Middle East; Southeast Asia; Latin America and Caribbean | 2009 | 2012 | Symptomatic | 2244b | 44.4 | Cohort | TST / IGRA | 10 | NI | NI | 30.30 |
Oeltmann [46] | 2008 | USA | Refugee | Thailand | 2004 | 2005 | Routine screening | 5637 c | 41.2 | Cross sectional | TST | 5 | NI | NI | 28.81 |
Banfield [39] | 2012 | Australia | Refugee | Sudan; Congo; Liberia; Burundi; Tanzania; Sierra Leone; Burma | 2006 | 2007 | Routine screening | 1004 c | 51.2 | Cross sectional | TST / IGRA | NI | NI | NI | 26.29 |
Tiong [42] | 2006 | Australia | Refugee | Western Africa; Central Africa; Eastern Africa; Africa | 2004 | 2005 | Both | 96 c | 55.8 | Cross sectional | TST / IGRA | 10 | NI | NI | 25.00 |
Gray [38] | 2012 | Australia | Refugee | Middle East; Africa; Asia; Australia | 2005 | 2010 | Routine screening | 328 b | 45.7 | Cross sectional | TST | 10 | NI | NI | 24.70 |
Sarivalasis [47] | 2012 | Switzerland | Asylum Seeker | Balkan Peninsula; Soviet Union; Asia; Africa | 2009 | 2010 | Routine screening | 393 c | 27.2 | Cross sectional | IGRA | NA | NI | NI | 23.66 |
Sheikh [44] | 2009 | Australia | Refugee | Asia; Middle East; Western Africa; Central Africa; Eastern Africa | 2005 | 2006 | Routine screening | 219 c | 53.1 | Cross sectional | TST | 10 | NI | NI | 23.29 |
Bennett [89] | 2014 | USA | Refugee | Middle East, Asia; Sub-Saharan Africa | 2010 | 2012 | Routine screening | 4280 b | 49.7 | Cohort | TST / IGRA | 10 | 23.4 | 15.8 | 21.40 |
Paxton [74] | 2012 | Australia | Refugee | NI | 2006 | 2009 | Routine screening | 810 c | 49.0 | Cohort | IGRA | NA | NI | NI | 20.86 |
Lucas [90] | 2010 | Australia | Refugee | Africa; Asia | 2007 | 2008 | Routine screening | 524 b | 51.9 | Cohort | TST / IGRA | 10 | NI | NI | 18.32 |
Johnston [56] | 2012 | Australia | Refugee | Asia; Africa | 2009 | 2010 | Routine screening | 176 c | 41.7 | Cohort | TST | 10 | NI | NI | 18.18 |
Marras [35] | 2003 | Canada | Refugee | India; Tibet; Nepal | 1998 | 2001 | Routine screening | 525 b | 32.0 | Cohort | TST | 10 | NI | NI | 16.0 |
Ramos [91] | 2010 | USA | Refugee | Iraq | 2007 | 2009 | Routine screening | 4923 c | 48.5 | Cross sectional | TST / IGRA | NI | NI | NI | 14.06 |
Bennet [53] | 2017 | Sweden | Asylum Seeker | Afghanistan; Somalia; Eritrea; Ethiopia | 2015 | 2016 | Routine screening | 2936 b | NI | Cohort | TST / IGRA | 10 | NI | NI | 11.34 |
Mockenhaupt [32] | 2016 | Germany | Refugee | Syria | 2011 | 2015 | Routine screening | 44 b | 34.1 | Cohort | NI | NI | NI | NI | 9.09 |
Liu [61] | 2015 | USA | Refugee | NI | 2007 | 2012 | Routine screening | 57,019 c | NI | Cross sectional | TST / IGRA | 10 | NI | NI | 7.93 |
Taylor [92] | 2016 | USA | Refugee | NI | 2010 | 2010 | Routine screening | 13,395 b | NI | Cohort | TST / IGRA | 10 | NI | NI | 6.20 |
Pavlopoulou [93] | 2017 | Greece | Mixed | Afghanistan; Congo; Bangladesh; Pakistan; Iran; Lebanon; Sudan; Kenia; Somalia; Eritrea | 2010 | 2013 | Routine screening | 162 b | 44.4 | Cross sectional | TST / IGRA | 10 | NI | NI | 4.94 |
Harling [68] | 2007 | UK | Asylum Seeker | Iraq; Afghanistan; Czech Republic; Iran; Congo; Somalia; Zimbabwe; Angola | 2002 | 2003 | Routine screening | 4275 c | 25.0 | Cross sectional | TST | NI | 2.4 | 0.9 | 2.18 |
Lee [36] | 2013 | USA | Refugee | Iraq; Burma; Bhutan; Iran; Cuba; Thailand; Vietnam; Nepal; Somalia | 2009 | 2009 | Routine screening | 78,899 b | NI | Cross sectional | TST / IGRA | 10 | NI | NI | 1.87 |
Yanni [72] | 2013 | Jordan | Refugee | Iraq | 2007 | 2009 | Routine screening | 13,669 c | 50.3 | Cohort | TST | 10 | NI | NI | 1.84 |
Entzel [94] | 2003 | USA | Refugee | Cuba | 1999 | 2000 | Routine screening | 241 c | NI | Cross sectional | TST | NI | NI | NI | 0.41 |
Abbreviations LTBI Latent Tuberculosis Infection, USA United States of America, UK United Kingdom, NI Not Informed, TST Tuberculin skin test, IGRA Interferon gamma release assay, NA Not applicable
In the column Setting, “both” means that the study performed routine screening and symptomatic evaluation
aHospitalised population; bTotal population total study; cPopulation screened for LTBI